Immunoediting represents a complex and dynamic process involving cancer and immune system cells, composed by three intertwined phases: elimination, equilibrium and escape. A large number of immune cell subtypes are involved, each playing a peculiar role in interacting with cancer cells: cytotoxic CD8+ T cells play a main role in cancer killing by inducing tumor cell death, while FOXP3+ T-regulatory cells represent an immune-inhibitory cell subtype. The evaluation of tumor infiltrating lymphocytes (TILs) in H&E routine samples has been shown to represent a reliable surrogate of the immune anti-tumor activity and a robust independent prognostic biomarker in breast cancer (BC) patients, especially in the Tripe Negative and HER2+ subtypes. The present review addresses the mechanisms of breast cancer immunoediting, its cell complexity and prognostic/predictive relevance, providing evidence that TILs represent one the most promising biomarkers for BC patients.
- Breast cancer
- Gene expression
- Tumor infiltrating lymphocytes
ASJC Scopus subject areas